(Q77495138)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797688%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

ERBB2 oncogene in human breast cancer and its clinical significance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797688%20AND%20SRC:MED&resulttype=core&format=json

Erb-b2 receptor tyrosine kinase 2

6 December 2019

main subject

1 reference

1 reference

F Révillion

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797688%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

J Bonneterre

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797688%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

J P Peyrat

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797688%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 May 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797688%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797688%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797688%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

791-808

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797688%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797688%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Molecular cloning and expression of an additional epidermal growth factor receptor-related gene

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

The type I growth factor receptors in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Expression of the ERBB3 gene product in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB-2 andras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Gene Amplification and Expression of the <i>neu </i>(c-erbB-2) Sequence in Human Mammary Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: frequency and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Correlation of erbB-2 gene amplification with low levels of estrogen and/or progesterone receptors in primary breast cancer: do erbB-2 products delineate hormone-independent tumors?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

The significance of oncogene amplification in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Cathepsin D assay in primary breast cancer and lymph nodes: Relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

HER-2 oncogene amplification and overall survival of breast carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

int-2 amplification in breast cancer: association with decreased survival and relationship to amplification of c-erbB-2 and c-myc

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Loss of heterozygosity at chromosome 17p is associated with HER-2 amplification and lack of nodal involvement in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Detection and temporal appearance of multiple copies of c-erb-B2 genes in advanced mammary carcinoma using fine needle biopsies and the polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Critical determination of the frequency of c-erbB-2 amplification in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Expression of c-erbB2, TGF-beta 1 and pS2 genes in primary human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

HER-2/neu oncogene protein and prognosis in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB-2 expression in benign and malignant breast disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB-2 protein expression in node negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB-2 oncoprotein expression in primary and advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Genomic alterations of the c-myc protooncogene in relation to the overexpression of c-erbB2 and Ki-67 in human breast and cervix carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Prognostic significance of c-erbB-2 expression in node negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB-2 oncoprotein in screen-detected breast carcinoma: an immunohistological study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Prognostic significance of Helix pomatia lectin and c-erbB-2 oncoprotein in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Stability of HER-2/neu expression over time and at multiple metastatic sites

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB-2 expression in different histological types of invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

C-erbB-2 oncogene product expression depends on tumour type and is related to oestrogen receptor and lymph node status in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma--a detailed morphological analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinomain situ

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

C-ERBB-2 oncogens protein inIn situ and invasive lobular breast neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

An immunohistochemical study of the presence of c-erbB-2 protein in Paget's disease of the nipple

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Expression of C-erbB-2 Oncoprotein in Mammary and Extramammary Paget's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Prognostic significance of TP53 alterations in breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

No additive impact on patient survival of the double alteration of p53 and c-erbB-2 in breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

c-erbB2 expression in correlation to other biological parameters of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

C-erbB-2 protein in the sera of breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910157-5

7 January 2021

10.1016/S0959-8049(97)10157-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797688%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference